Chris Bulman’s Gilead Sciences GILD Stock Holding History

Chris Bulman’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$218K	Sell	1,563 -114	-7%	-$16K	0.1%	137
2025 Q4	$206K	Buy	+1,677	New	+$204K	0.09%	142
2025 Q3	–	Sell	-2,092	Closed	-$232K	–	145
2025 Q2	$232K	Buy	+2,092	New	+$223K	0.13%	109
2024 Q3	–	Sell	-1,658	Closed	-$114K	–	235
2024 Q2	$114K	Buy	+1,658	New	+$111K	0.08%	130

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Chris Bulman's GILD Position: Q1 2026 in Review

Chris Bulman reduced its Gilead Sciences (GILD) stake by 6.8% in Q1 2026, selling an estimated $16K and leaving 1,563 shares worth $218K. The position accounts for 0.1% of the portfolio, ranked #137.

Chris Bulman first reported a position in GILD in Q2 2024 and has held it in 4 quarters since. The position peaked at $232K in Q2 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Chris Bulman held 1,563 shares of Gilead Sciences worth $218K as of Q1 2026.
Chris Bulman sold 114 Gilead Sciences shares in Q1 2026, an estimated $16K.
Gilead Sciences made up 0.1% of Chris Bulman's portfolio in Q1 2026, its #137 holding.
Chris Bulman first reported a position in Gilead Sciences in Q2 2024 and has held it in 4 quarters since.
Chris Bulman's Gilead Sciences position peaked at $232K in Q2 2025.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Chris Bulman's 13F filing for Q1 2026, filed 13 Apr 2026.